Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 9.89
+0.46 (4.88%)
Jan 21, 2026, 4:08 PM HKT
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 9.13 billion as of January 21, 2026. Its market cap has increased by 162.18% in one year.
Market Cap
9.13B
Enterprise Value
7.63B
Revenue
861.24M
Ranking
n/a
PE Ratio
36.42
Stock Price
9.89
Market Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has decreased from 12.11B to 9.13B, a decrease of -24.58%. That is a compound annual growth rate of -4.51%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 20, 2026 | 9.13B | -3.78% |
| Dec 31, 2025 | 9.49B | 181.80% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Everest Medicines | 13.55B |
| Ascletis Pharma | 13.39B |
| Mirxes Holding Company | 11.61B |
| HBM Holdings | 10.81B |
| Shanghai Haohai Biological Technology | 10.81B |
| Nanjing Leads Biolabs | 10.44B |
| Lepu Biopharma | 9.53B |
| Abbisko Cayman | 9.33B |